Consistent with this, selonsertib (GS-4997), an ASK1 inhibitor developed as an antifibrotic agent for nonalcoholic steatohepatitis,16 reduced cardiac fibrosis, and remodeling in mice treated with Ang II. The gene discussed is AGT; the disease is metabolic dysfunction-associated steatohepatitis.